placebo + alfuzosin

Alfuzosin is a small molecule pharmaceutical drug classified as an alpha-1 adrenergic receptor antagonist (alpha blocker). It is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate gland in men. By selectively inhibiting alpha-1 adrenergic receptors in the lower urinary tract, alfuzosin relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing urinary symptoms such as frequent or urgent urination, weak stream, and incomplete bladder emptying. Alfuzosin does not shrink the prostate but alleviates symptoms associated with its enlargement[1][2][3][4][5]. Placebo is an inactive substance used as a control in clinical trials; it has no pharmacological effect. The combination "placebo + alfuzosin" refers to a clinical trial arm where both placebo and active drug are administered together or compared for study purposes.